Diamyd Medical finalizing Phase 3 screening as GMP review progresses
The number of randomized participants in DIAGNODE-3, Diamyd Medical’s registrational Phase 3 trial in type 1 diabetes, has now exceeded 290, and the screening will conclude in the coming weeks. The interim efficacy analysis of approximately 170 participants with 15-month data is scheduled for end of March 2026. The Company also confirms that its Umeå manufacturing facility is currently under review by the Swedish Medical Products Agency as part of the GMP-certification process.“Finalizing the screening phase is a major milestone and a significant achievement by all participating clinics in